Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Veliparib
Cancer Or Benign Tumor
National Cancer Institute (NCI)
P1
CCC
(52)
Azacytidine
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Berzosertib
Neuroendocrine Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Etoposide
B-Cell Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(52)
Ipilimumab
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Navitoclax
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(52)
Oxodotreotide
Esthesioneuroblastoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Prednisone
Lymphoid Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(52)
Prednisone
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Sirolimus
Melanoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Trastuzumab Deruxtecan
Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Uproleselan
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
National Cancer Institute (NCI)
P1/2
CCC
(52)
Veliparib
Lung Large Cell Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(52)
Venetoclax
Lymphoid Neoplasm
National Cancer Institute (NCI)
P1/2
CCC
(52)
Vidutolimod
Melanoma
National Cancer Institute (NCI)
P2/3
CCC
(52)
ad5 cea vaccine
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Aspirin
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Balstilimab
Nonpapillary Renal Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Berzosertib
Castration-Resistant Prostate Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Botensilimab
Nonpapillary Renal Cell Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Capivasertib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Capivasertib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Carboplatin
Myelofibrosis
National Cancer Institute (NCI)
P2
CCC
(51)
Ceritinib
Lung Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
Showing 2251 to 2275 of 3,272 assets
Previous
Page 91 of 131
Next